All
The Importance of Building in Flexibility and Commercial Viability Early in the CGT Scaling Process
October 7th 2025At the Cell and Gene Meeting on the Mesa, a panel discussion was held on advanced therapy production and how it demands modular platforms, automation, and data governance to drastically improve patient access and affordability.
DemeRx’s Neuroplastogen Candidate Signals New Alcohol Use Disorder Approach
October 7th 2025The awarded $1.7 million in funding will support the company’s preclinical and clinical progress on DMX-1001 (noribogaine), designed to reduce relapse and improve brain health in patients with alcohol use disorder.
Collaborating on the Development of Radiopharmaceuticals
October 6th 2025Pharmaceutical Technology® spoke with Juliana Maynard, PhD, Head of Translational Imaging at Medicines Discovery Catapult, to find out what makes radiopharmaceuticals unique and how MDC’s collaboration with Crown Bioscience can help developers of these treatments for cancer.
Advancing Radiopharmaceutical Development
October 2nd 2025Pharmaceutical Technology® spoke with Juliana Maynard, PhD, Head of Translational Imaging, at Medicines Discovery Catapult, to find out what makes radiopharmaceuticals unique and how MDC’s collaboration with Crown Bioscience can help developers of these treatments for cancer.
Radiopharmaceuticals: A Development Platform
September 26th 2025Pharmaceutical Technology® spoke with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, to learn more about Crown Bioscience’s collaboration with Medicines Discovery Catapult on a new development platform for radiopharmaceuticals.
Ask the Expert: Questions about Real-World Evidence and Supply Chain Security
September 25th 2025In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates, and Siegfried Schmitt, PhD, Parexel, answer questions on the use of real-world evidence for both small-molecule and large-molecule drug development. In addition, they tackle a question on supply chain security problems that arise during transportation of pharmaceutical goods.
Stakeholders React to FDA's Push for Quality, Integrity, and Uniformity
September 24th 2025The FDA draft guidance "Considerations for Complying with 21 CFR 211.110" raises points to consider regarding drug products made using advanced manufacturing, batch uniformity, drug product integrity, and how manufacturers can incorporate process models into control strategies.